Eli Lilly is the dominant player in incretin obesity and diabetes care. Tirzepatide — Mounjaro for type-2 diabetes, Zepbound for obesity — generated the bulk of 2025 growth, and SURMOUNT-5, the first definitive Phase 3B head-to-head against semaglutide, read out 21.6% mean weight loss at 72 weeks versus semaglutide's 15.4%. Q1 2026 revenue reached $19.8 billion (+56% YoY) on Mounjaro $8.66B (+125%) and Zepbound $4.16B (+80%); Lilly raised 2026 guidance to $82–85B on April 30 and the stock climbed 6.11% on May 1. On May 4, an FAERS hepatic-failure case for Foundayo surfaced, sending shares down 3% premarket before recovering on Lilly's safety-data response and an RBC 'baseline noise' defense.
The next layer determines 2027 and beyond. Orforglipron, marketed as Foundayo, became the first small-molecule oral GLP-1 cleared for obesity in April 2026 and reached roughly 20,000 patients and more than 8,000 prescribers in its first three weeks, though Wegovy pill outpaced it ~20× in early-May IQVIA volume. Retatrutide, the GLP-1/GIP/glucagon triple agonist, posted its first Phase 3 type-2 diabetes readout (TRANSCEND T2D1: A1c down 1.7–2.0 pts, 25–37 lb mean weight loss) on the April 30 call alongside the prior TRIUMPH-4 obesity-with-knee-osteoarthritis data. The retatrutide MASLD Phase 3 (NCT06859268) is enrolling, building on 86% Phase 2 liver-fat reduction. LillyDirect handles self-pay distribution.
The company has spent 2024 and 2025 building peptide CDMO capacity to support both branded volume and the long shadow of the compounding fight. Stories here track the pipeline, deals, and the share-price moves that follow them.
Eli Lilly's retatrutide MASLD Phase 3 program (NCT06859268) continues enrollment across multiple international sites following the December 2025 Phase 2 readout that documented 86% mean liver-fat reduction at 48 weeks on 12 mg dosing. The Phase 3 trial enrolls adults with biopsy-confirmed MASH stages F2-F3 with primary endpoint at week 52 measuring MASH resolution without worsening of fibrosis. The 86% liver-fat reduction substantially exceeds the resmetirom 38-46% benchmark from the MAESTRO-NAFLD-1 reference cohort. Topline data is expected H1 2027; full results at AASLD or EASL 2027. The MASLD Phase 3 sits alongside TRIUMPH-3 (obesity + CVD) and TRIUMPH-OUTCOMES (10,000-patient cardiovascular outcomes trial reading 2027) as the second 2027 retatrutide catalyst. If positive, retatrutide files for MASH labeling alongside the obesity NDA — potentially within the same FDA submission window.
A May 21 Research and Markets report projected the global GLP-1 receptor agonist weight loss drug market expanding from $15.5B in 2025 to $18.02B in 2026 — a 16.3% compound annual growth rate. The forecast tracks through 2030 and 2035 across major players Novo Nordisk, Eli Lilly, and Pfizer, plus the growing oral GLP-1 segment (Wegovy pill, Foundayo, Structure Therapeutics' aleniglipron entering Phase 3). By 2020 roughly 4 million people were on GLP-1s; by 2026 that estimate has reached 30 million. The market data is the formal backdrop for the broader 2026 obesity-pharmacology conversation: GLP-1 alone is now larger than the 2024 oncology drug class's largest single product. The IQVIA peptide-CDMO capacity-build wave (Bachem, PolyPeptide, CordenPharma SPPS expansions through 2028) and the Lilly $4.5B Lebanon Indiana investment lean directly into the demand projection.
Eli Lilly announced TRIUMPH-1 topline results May 21 from the 80-week Phase 3 registrational trial of retatrutide — a first-in-class GIP/GLP-1/glucagon triple-receptor agonist — in 2,339 adults with obesity or overweight and at least one weight-related comorbidity, without diabetes. Mean body weight loss was 28.3% (70.3 lbs) at 12 mg, 25.9% at 9 mg, and 19.0% at 4 mg, all versus 2.2% on placebo. All three doses met the primary and key secondary endpoints. 45.3% of participants achieved ≥30% weight loss — bariatric-surgery territory. A 104-week extension in adults with baseline BMI ≥35 saw mean weight loss reach 30.3% (85.0 lbs) on 12 mg. Full data presentation is scheduled for ADA 2026 in New Orleans (June 5-8). Lilly's NDA filing follows the TRIUMPH-2 (obesity + T2D) and TRIUMPH-3 (obesity + established cardiovascular disease) readouts expected later in 2026.
5W Public Relations published the fourth installment of its AI Visibility Index, finding two manufacturers — Novo Nordisk and Eli Lilly — account for nearly 100% of GLP-1-class citations inside ChatGPT, Claude, Perplexity, and Google AI Overviews. Five products — Wegovy, Zepbound, Ozempic, Mounjaro, and Saxenda — capture about 57% of all weight-loss-and-metabolic-health category citations. Founder Ronn Torossian attributes the citation moat to peer-reviewed clinical data cadence, named-author editorial coverage, and regulatory events treated as content events, with content velocity outpacing the broader news cycle.
Wall Street's mid-May Lilly outlook is firmly bullish. Barclays analyst Emily Field raised her LLY price target to $1,400 from $1,350 (Overweight) citing tirzepatide momentum and the easing concerns around Foundayo's launch trajectory. Cantor Fitzgerald lifted its target to $1,230 with an Overweight rating on Mounjaro demand and Foundayo PBM coverage activation. Motley Fool's May 17 commentary settled on $1,085 with a buy rating and 70% confidence, citing the company's raised 2026 guidance ($82-85B revenue) after one quarter as the deciding factor. The combined analyst view: Q1's $19.8B revenue print (+55.5% YoY) and Mounjaro's $8.66B quarter — which displaced Keytruda as the world's #1 best-selling drug — anchor the upside case while Foundayo's Week 5 acceleration removes the launch-trajectory overhang.
Motley Fool's May 17 analysis framed retatrutide — Eli Lilly's triple GIP/GLP-1/glucagon receptor agonist — as the molecule positioned to displace both semaglutide (Wegovy) and tirzepatide (Zepbound) from the obesity therapeutics top spot. The thesis rests on TRIUMPH-1 (general obesity without T2D, 80 weeks, pivotal NDA-supporting trial) and TRIUMPH-2 (obesity + T2D) readouts expected Q2-Q3 2026. TRIUMPH-4 already reported a 28.7% mean weight reduction at the 12 mg dose at 68 weeks — well above the 21% standard Wegovy 2.4 mg and the 22.5% Zepbound 15 mg ceilings. If TRIUMPH-1 confirms the 25%+ weight-loss range, retatrutide's NDA filing follows in late 2026 / early 2027 with approval mid-2027. The full TRIUMPH program runs eight pivotal trials with >5,800 participants plus a separate 10,000-patient cardiovascular outcomes trial reading out in 2027.
Eli Lilly's TRIUMPH program for retatrutide — a triple GIP/GLP-1/glucagon receptor agonist — has TRIUMPH-1 (general obesity without T2D, 80 weeks, 2,007 participants) and TRIUMPH-2 (obesity + T2D) reading out in Q2-Q3 2026. Both are pivotal for the planned NDA filing. The earlier TRIUMPH-4 readout in December 2025 delivered 28.7% mean weight loss at 68 weeks on 12 mg dosing with 75% knee osteoarthritis pain reduction. The full TRIUMPH program runs eight pivotal trials with >5,800 participants total: obesity, T2D, OSA, MASLD, knee OA, cardiovascular outcomes (TRIUMPH-OUTCOMES, ~10,000 patients reading out 2027), and dose-extension studies. A new safety signal noted in Phase 2 — a small uptick in mild-to-moderate hepatic enzyme elevations on 12 mg dosing — will be monitored carefully in Phase 3 readouts. Lilly's $4.5B Lebanon Indiana investment (announced May 6) targets retatrutide manufacturing capacity ahead of the 2027 approval window.
Eli Lilly executives confirmed on the April 30 Q1 call that a full direct-to-consumer TV advertising campaign for Foundayo (orforglipron) launches in late May 2026, coinciding with the mid-May commercial access activation at two of the three largest US pharmacy benefit managers. The campaign emphasizes Foundayo's only-oral-GLP-1-without-food-or-water-restrictions positioning vs Novo's Wegovy pill, which requires fasting administration. Lilly previously held back consumer advertising through the first six weeks of launch to let PBM coverage scale before driving consumer prescription demand. Citi's May 8 IQVIA note flagged the upcoming campaign and PBM expansion as the catalysts for the Week 5+ trajectory acceleration that landed in the May 8 IQVIA print (10,248 scripts, +40% w/w).
Citi's Friday May 15 client note reported Foundayo (orforglipron) hit 10,248 US prescriptions in the week ending May 8 per IQVIA — the first 40% week-over-week jump in the launch series. Week-by-week trajectory: 1,390 (Week 1), 3,707 (Week 2), 5,612 (Week 3), 7,335 (Week 4), 10,248 (Week 5). The acceleration aligns with mid-May commercial access activation at two of the three largest US PBMs that Lilly flagged on the April 30 Q1 call. Citi maintained $146M Q2 revenue and $1.6B full-year 2026 estimates. The Wegovy pill remains ahead — Novo CEO Doustdar's May 14 commentary confirmed >1M cumulative US users since the January 5 launch — but the gap is narrowing as Foundayo's PBM coverage comes online and telehealth volume (~35% of total per Lilly executives, not captured in retail-only IQVIA data) layers on top.
Eli Lilly executives' Q1 commentary clarified the Foundayo launch-channel mix: roughly 45% via LillyDirect (the company's direct-to-patient pharmacy), 35% via telehealth platforms not captured in retail-only IQVIA data, and 20% via traditional retail pharmacy fills. The split helps explain the apparent gap between Citi's IQVIA-reported 10,248 Week 5 prescriptions and the 20,000+ patient count Lilly disclosed on the April 30 Q1 call. The pattern suggests Foundayo is being adopted preferentially through digitally-enabled care channels — Hims & Hers, LifeMD, JoinFound, and other telehealth platforms with weight-management Rx infrastructure — rather than primary-care prescribing. The mix is structurally similar to the Wegovy pill launch but with a higher telehealth share. The implication for the next 90 days: PBM coverage expansion (mid-May) and brand-name TV advertising (launching late May per the Q1 commentary) will drive most of the next leg of growth.
Eli Lilly's $7.8B Centessa Pharmaceuticals partnership announced in March 2026 continues to anchor the company's pipeline diversification beyond the GLP-1 franchise. Centessa's lead programs include orexin-2 receptor agonist peptides for narcolepsy and other CNS indications, with multiple Phase 1/2 readouts due across 2026-2027. The deal joins Lilly's $7B Kelonia Therapeutics acquisition (in vivo CAR-T platform) and $2.25B Profluent collaboration (AI-designed recombinase genetic medicine) as part of a multi-vertical diversification strategy. The $4.5B Lebanon Indiana LEAP District expansion announced May 6 (for Foundayo and retatrutide manufacturing) signals the GLP-1 franchise remains the cash cow, but the company is actively building optionality outside the obesity-pharmacology lane heading into the 2031 tirzepatide patent cliff.
The next Foundayo IQVIA prescription tracker update is expected from Citi mid-week May 18-20, covering the week ending May 8. Week 4 hit 7,335 prescriptions per the May 8 Citi note with Lilly executives citing 20,000 total patients (~35% via telehealth not captured in the retail-only IQVIA data). Citi's projected $146M Q2 revenue and $1.6B full-year 2026 estimate continue to anchor the analyst consensus. Lilly executives have asked analysts for 8-12 weeks of data before reading commercial trajectory through pharmacy-fill noise; the Week 5 reading is the first post-PBM-coverage-expansion data point as the two largest US PBMs went live with Foundayo coverage mid-May. The Wegovy pill remains roughly 60-70x ahead on weekly volume (>440K in the week ending May 1 per Novo's Q1 commentary).
Eli Lilly published SURMOUNT-MAINTAIN in The Lancet and ATTAIN-MAINTAIN in Nature Medicine on May 12, with concurrent presentation at ECO 2026 in Istanbul. SURMOUNT-MAINTAIN tested lower-dose Zepbound (tirzepatide 5 mg) vs maximum tolerated dose: at week 112, MTD preserved all weight loss while the 5 mg arm lost only 5.6 kg additional. ATTAIN-MAINTAIN tested Foundayo (orforglipron) as a switch from injectable GLP-1s in SURMOUNT-5 participants: orforglipron preserved 79.3% of injectable-phase weight loss vs 37.6% on placebo at week 52; Wegovy MTD switchers regained only 0.9 kg, Zepbound MTD switchers regained 5.0 kg. The dual readout reframes the maintenance-versus-discontinuation conversation: dose-tapering and oral-switching strategies now have Phase 3 evidence behind them, validating the long-term-treatment chronic-disease framing.
Sector stock reaction across May 12-13: Novo Nordisk ADRs popped roughly 6% premarket May 12 on the early-responder + women's-data combination and the OASIS 4 mobility analyses; Eli Lilly traded flat as the SURMOUNT-MAINTAIN and ATTAIN-MAINTAIN dual publication confirmed expected maintenance positioning rather than producing fresh upside surprises. Analysts noted the broader 'long-term treatment' thesis — that GLP-1 obesity drugs are chronic-disease medications, not short courses — got concrete trial backing this week between SURMOUNT-MAINTAIN, ATTAIN-MAINTAIN, and STEP UP early-responder analyses. The week's narrative shift sets up the May 14-15 ECO Day 3+4 cycle and the May 29-June 2 ASCO 2026 meeting in Chicago — where peptide-drug conjugates (Bicycle BT8009, Avacta AVA6000, Pfizer FAP-Dox) take the next round of clinical-data spotlights.
Bloomberg reported May 6 that Eli Lilly's Mounjaro displaced Merck's Keytruda as the world's best-selling pharmaceutical in Q1 2026 — $8.66B Mounjaro Q1 sales vs Keytruda's $7.9B Q1 sales. The Mounjaro+Zepbound combined tirzepatide platform generated $36.5B in 2025, outpacing Keytruda's $31.6B. Keytruda had held the #1 ranking since Q1 2023, when it displaced AbbVie's Humira. The shift is the first time a peptide therapeutic has taken the top spot since the historical run of insulin biosimilars. The narrative also frames Lilly's $4.5B Lebanon Indiana manufacturing recommitment and the broader $21B Indiana capital plan as the supply-chain answer to demand at that scale.
Eli Lilly's Foundayo (orforglipron) reached UAE pharmacies on May 12 in Abu Dhabi, expanding from the April Dubai launch. The Emirates Drug Establishment first approved Foundayo on April 3, making the UAE the second country globally to register the once-daily oral GLP-1 pill. Pricing runs from AED 773/month for the 0.8 mg starter dose to AED 1,599/month for the 17.2 mg highest dose. Abu Dhabi has folded Foundayo into the emirate's broader weight-loss program, signaling government coverage rather than purely self-pay. The launch is one of the first international rollouts since FDA approval April 1; Lilly executives have framed UAE prescribing patterns and patient adherence as an early read on geriatric and Middle East regional patient response.
Eli Lilly on May 6 cut the ribbon on Lilly Lebanon Advanced Therapies — the company's first dedicated genetic medicine manufacturing facility — and committed an additional $4.5B across two more LEAP Research and Innovation District sites in Lebanon, Indiana. The new investment supports planned production of Foundayo (orforglipron), Lilly's only FDA-approved GLP-1 pill that does not require fasting or water restrictions, and retatrutide, the triple GLP-1/GIP/glucagon agonist in seven Phase 3 trials. Total Indiana capital commitments since 2020 now exceed $21B, with the LEAP District alone totaling $18B since 2022 — the largest capital project in Indiana history. The buildout will add more than 1,000 jobs by 2027 and gives Lilly a domestic Foundayo + retatrutide supply chain independent of peptide-CDMO bottlenecks.
A post-hoc subgroup analysis of Eli Lilly's orforglipron (Foundayo) in adults aged 65 and older, drawn from the ATTAIN-1 and ATTAIN-2 Phase 3 programs, will be presented at ECO 2026 in Istanbul May 12-15. The analysis pools 616 randomized participants (613 treated) — 118 on 6 mg, 135 on 12 mg, 146 on 36 mg orforglipron, and 214 placebo — across patients with and without type 2 diabetes. The geriatric data set addresses a long-standing clinical gap: incretin trials have systematically underenrolled adults over 65, the population most affected by obesity-related comorbidities and the most likely to face polypharmacy-related GI tolerability concerns. Lead author Dr. Deborah Horn (UTHealth Houston McGovern Medical School). The presentation is among the ECO 2026 abstracts that will shape geriatric prescribing patterns for the first FDA-approved GLP-1 pill that does not require fasting or water restrictions.